Loading
institutionsInstitution
Cancer Hospital, Chinese Academy of Medical Sciences
The CAMS Cancer Hospital is China's national cancer centre, leading regulatory-grade trials of domestic ADCs and PD-1 antibodies.
Overview
The Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing is China's national cancer centre, ranked fiftieth in the Newsweek/Statista oncology list, and a lead site for regulatory-grade trials of domestic antibody-drug conjugates and PD-1 antibodies. It led pivotal Chinese studies including DAWNA-1 and the development of sacituzumab tirumotecan, known as SKB264, and disitamab vedotin, with Yuankai Shi, Jie Wang, Fei Ma, Jing Huang and Binghe Xu among the clinicians OnCo lists. OnCo links it to oesophageal cancer, to the CSCO guidelines, to Peking Union Medical College Hospital and the NMPA, and to the idea of family-based Helicobacter pylori test-and-treat to prevent stomach cancer. Regulatory divergence between regions is the bottleneck its work bears on most. Its national trials and ADC programmes are listed below.
Location
Beijing, CN
Type
cancer center
Website
Newsweek 2026 oncology rank
#50
OnCo score
#101 · 38 points (10 Newsweek + 0 NCI + 28 from 14 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Cancer Hospital of Chinese Academy of Medical Sciences, including child institutions. 365 works · 3,800 citations · 77% open access · 18% clinical trials · 2% reviews.
Oncology works per year
952022
702023
742024
592025
672026
Most works
- Xiaojia Wang12 works
- Binghe Xu10 works
- Jiang‐Jiang Qin9 works
- Shuangmei Zou9 works
- Jianqing Zhu8 works
- Shuai Jiao8 works
- Haiyi Liu8 works
- Xishan Wang8 works
- Xu Guan7 works
- Lingbin Du6 works
Most cited
- National trials
- ADC development
Binghe Xu
Professor of Medical Oncology; Director, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences
Breast cancerAntibody-drug conjugatesTROP2
Principal investigator of OptiTROP-Breast01, the Chinese trial that got the TROP2 ADC sacituzumab tirumotecan approved before any Western approval.
Fei Ma
Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences
Breast cancerHER2Antibody-drug conjugates
A breast oncologist who led Chinese pyrotinib and ADC trials and studies of ctDNA in HER2-positive disease.
Jie He
President, Cancer Hospital, Chinese Academy of Medical Sciences; Director, National Cancer Center of China; thoracic surgeon
Thoracic surgeryLung and oesophageal cancerCancer registry and statistics
Runs China's national cancer centre and the registry that reports the country's cancer statistics.
Jie Wang
Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences
Lung cancerImmunotherapyTargeted therapy
Led the RATIONALE trials of tislelizumab in lung cancer and many other Chinese registrational NSCLC studies.
Jing Huang
Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences
Oesophageal cancerImmunotherapyClinical trials
Principal investigator of ESCORT, the trial that established camrelizumab in oesophageal squamous cell carcinoma.
Yuankai Shi
Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences
Lung cancerLymphomaDrug development
A medical oncologist who has led many of China's registrational trials of domestically developed targeted agents and antibodies.
Similar pages
- InstitutionSun Yat-sen University Cancer Center
Shares CSCO guidelines (China), Chinese Society of Clinical Oncology, National Medical Products Administration / Center for Drug Evaluation, Trials do not represent the people who get cancer.
- TrialESCORT-1st
Shares Jing Huang, Oesophageal cancer.
- InstitutionNational Healthcare Security Administration
Shares National Cancer Center of China, National Medical Products Administration / Center for Drug Evaluation, Most of the world has almost no cancer care.
- TreatmentPyrotinib
- TermChina Drug Administration Law (2019) and expedited pathways
Shares National Medical Products Administration / Center for Drug Evaluation, Regulatory divergence between regions, Most of the world has almost no cancer care.
- InstitutionPeking University Cancer Hospital
Shares CSCO guidelines (China), Disitamab vedotin, Oesophageal cancer.
- InstitutionWest China Hospital, Sichuan University
Shares Chinese Society of Clinical Oncology, Most of the world has almost no cancer care.
- IdeaOne multiregional trial, no bridging studies: enforce ICH E17 in Japan and China
Shares Trials do not represent the people who get cancer, Regulatory divergence between regions.
cancers
drugs
ApprovedADC
ApprovedADC